97 related articles for article (PubMed ID: 14730476)
1. Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?
Schulman S
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():33-6. PubMed ID: 14730476
[TBL] [Abstract][Full Text] [Related]
2. Factor Xa is a superior target to factor IIa for antithrombotic therapies.
Büller HR
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():37. PubMed ID: 14730477
[No Abstract] [Full Text] [Related]
3. New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Ansell J
Curr Hematol Rep; 2004 Sep; 3(5):357-62. PubMed ID: 15341703
[TBL] [Abstract][Full Text] [Related]
4. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
5. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
6. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa inhibitors: today and beyond.
Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
[TBL] [Abstract][Full Text] [Related]
8. [New oral anticoagulants - influence on coagulation tests].
Simeon L; Nagler M; Wuillemin WA
Dtsch Med Wochenschr; 2014 Jan; 139(3):94-9. PubMed ID: 24399657
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
10. Emerging anticoagulants: mechanism of action and future potential.
Klement P; Rak J
Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
12. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
Andersen JC
Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
[TBL] [Abstract][Full Text] [Related]
13. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Oldgren J; Johnston N; Siegbahn A
Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant drugs: an update.
Kwaan HC; Samama MM
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):511-22. PubMed ID: 15225111
[TBL] [Abstract][Full Text] [Related]
15. [Rivaroxaban: mode of action].
Drouet L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
[TBL] [Abstract][Full Text] [Related]
16. Long-term anticoagulation: the prospects for alternatives to warfarin.
Ansell J
Semin Vasc Surg; 2005 Sep; 18(3):134-8. PubMed ID: 16168888
[TBL] [Abstract][Full Text] [Related]
17. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
[TBL] [Abstract][Full Text] [Related]
18. The clinical implications of new oral anticoagulants: will the potential advantages be achieved?
Phillips KW; Ansell J
Thromb Haemost; 2010 Jan; 103(1):34-9. PubMed ID: 20062925
[No Abstract] [Full Text] [Related]
19. [Factor Xa-inhibition in interventional cardiology].
Ahrens I; Peter K; Bode C
Hamostaseologie; 2007 Dec; 27(5):328-32. PubMed ID: 18060241
[TBL] [Abstract][Full Text] [Related]
20. New anticoagulants for atrial fibrillation.
De Caterina R; Kristensen SD; Renda G
J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
